This week CPHI 2023 will unite industry leaders, innovators, and start-ups to explore sustainable solutions, cutting-edge technologies, and collaborative partnerships.
In a significant financial milestone, Xlife Sciences AG invests CHF23.3m in 4D Lifetec AG. With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an AI software developed specifically for 4D Lifetec, which will massively expand the functionality of the 4D Lifetest in the field of digital health. The strategic investment marks a significant turning point in the healthcare industry as it combines financial strength with cutting-edge technology to revolutionize early cancer detection.
4D Lifetec, a pioneer in early cancer detection, owns an immuno-oncology biomarker that has proven its high sensitivity already in cancer stages I and II in numerous clinical studies. The easy-to-use IVD certified blood test enables a unique high-throughput analysis of patient samples, providing a powerful data set that now becomes accessible to train AI through the transaction. Backed up with a substantial investment, 4D Lifetec gains a doorway to innovative AI that will redefine the landscape of cancer diagnosis and access to the digital health network of Xlife Sciences. In addition, the deal also provides the financial strength necessary for implementation.
Zurich-based Xlife Sciences is a publicly traded accelerator and investor company dedicated to addressing unmet medical needs and improving the quality of life through innovative healthcare solutions. Xlife Sciences was among the first to recognize the importance of artificial intelligence in enhancing patient care and outcomes and has built relevant capabilities within its portfolio companies. For early cancer diagnostics, AI resources were pooled in x-diagnostics, which can now unleash its full potential in a clinical context through the transaction. By becoming a new major shareholder in 4D Lifetec, Xlife Sciences adds a leading early cancer diagnostics pioneer to its portfolio network.
Bringing these two technologies together will enable 4D Lifetec to seamlessly integrate data from diverse sources, including patient history, genetic information, and imaging, providing comprehensive decision support for oncologists Dr. Arne-Christian Faisst, Co-founder and Chairman of 4D Lifetec says. This will result definitively in more accurate early cancer diagnoses, ultimately enhancing patient care and outcomes.
SpliceBio has licenced its intein technlogy to Roche’s gene therapy subsidiary Spark Therapeutics to develop a gene therapy targeting an undisclosed inherited retinal disease.
Antiverse Ltd and GlobalBio Inc. have extend their cancer antibody partnership to progress two PD-1 modulators to preclinial development
Sotio hsd licenced Synaffix ADC platform for up to US$740m to develop up to three next generation bioconjugates.
On Sunday, the World Health Summit with more than 300 speakers officially kicked off in Berlin. The three day event focuses on climate change and health, pandemic prevention, and digital technologies.
Dutch Synerkine Pharma BV has closed a Seris A extension financincg at €12.1m to accelerate clinical development of its pain killer SK-01.
A method to quickly classify central nervous system (CNS) tumours, combining rapid sequencing and deep-learned AI models, may enable molecular diagnosis in less than 90 minutes, Dutch researchers report.
Belgian fibrosis specialist Agomab Therapeutics NV has raised US$100m to advance development of its pipeline.
Alzheimers specialist AstronauTx Ltd has closed a £48m Series A financing to create new treatments for Alzheimers diseas